Novel Questionnaires for Assessing Signs and Symptoms of Eosinophilic Esophagitis in Children.

Allergy Clinical outcome assessment EoE Eosinophilic esophagitis Observer-reported outcome Patient-reported outcome Pediatric Quality of life Symptoms

Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
07 2022
Historique:
received: 26 05 2021
revised: 31 01 2022
accepted: 01 02 2022
pubmed: 11 4 2022
medline: 14 7 2022
entrez: 10 4 2022
Statut: ppublish

Résumé

Pediatric patients with eosinophilic esophagitis (EoE) experience heterogeneous symptoms and the patient's age may preclude reliable self-report of symptoms. The goal of this study was to develop a patient-reported outcome and an observer-reported outcome questionnaire to evaluate the signs and symptoms of EoE in pediatric patients (≥1 to <12 y of age) in a clinical trial setting. A concept-focused literature review, expert advice meetings, and concept elicitation interviews with pediatric EoE patients and their caregivers were conducted to identify disease-related signs and symptoms. Instructions, items, and response options were drafted. Cognitive debriefing interviews were conducted to evaluate children's and caregivers' ability to understand and respond to the questionnaires and to evaluate the comprehensiveness of the concepts measured. Results from the literature review, expert advice meetings (n = 6), and concept elicitation interviews (n = 24) informed the development of the Pediatric Eosinophilic Esophagitis Sign/Symptom Questionnaire intended for use by patients (PESQ-P) with EoE 8 years or older to younger than 12 years and an observer-reported outcome questionnaire planned for use by caregivers of patients (PESQ-C) 1 year old or older to younger than 12 years. Both questionnaires measure the same concepts; the PESQ-P assesses the frequency, duration, and/or severity of symptoms and the PESQ-C assesses the presence/absence of the signs/symptoms. The cognitive debriefing interviews (n = 17) demonstrated that participants were able to comprehend and complete the questionnaires as intended. This study provides evidence of the content validity of 2 novel questionnaires, PESQ-P and PESQ-C, designed to evaluate the symptom experience of pediatric EoE patients in a clinical trial setting.

Sections du résumé

BACKGROUND
Pediatric patients with eosinophilic esophagitis (EoE) experience heterogeneous symptoms and the patient's age may preclude reliable self-report of symptoms.
OBJECTIVE
The goal of this study was to develop a patient-reported outcome and an observer-reported outcome questionnaire to evaluate the signs and symptoms of EoE in pediatric patients (≥1 to <12 y of age) in a clinical trial setting.
METHODS
A concept-focused literature review, expert advice meetings, and concept elicitation interviews with pediatric EoE patients and their caregivers were conducted to identify disease-related signs and symptoms. Instructions, items, and response options were drafted. Cognitive debriefing interviews were conducted to evaluate children's and caregivers' ability to understand and respond to the questionnaires and to evaluate the comprehensiveness of the concepts measured.
RESULTS
Results from the literature review, expert advice meetings (n = 6), and concept elicitation interviews (n = 24) informed the development of the Pediatric Eosinophilic Esophagitis Sign/Symptom Questionnaire intended for use by patients (PESQ-P) with EoE 8 years or older to younger than 12 years and an observer-reported outcome questionnaire planned for use by caregivers of patients (PESQ-C) 1 year old or older to younger than 12 years. Both questionnaires measure the same concepts; the PESQ-P assesses the frequency, duration, and/or severity of symptoms and the PESQ-C assesses the presence/absence of the signs/symptoms. The cognitive debriefing interviews (n = 17) demonstrated that participants were able to comprehend and complete the questionnaires as intended.
CONCLUSIONS
This study provides evidence of the content validity of 2 novel questionnaires, PESQ-P and PESQ-C, designed to evaluate the symptom experience of pediatric EoE patients in a clinical trial setting.

Identifiants

pubmed: 35398552
pii: S2213-2198(22)00331-2
doi: 10.1016/j.jaip.2022.02.049
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1856-1863.e3

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Siddhesh Kamat (S)

Regeneron Pharmaceuticals, Health Economics and Outcomes Research, Medical Affairs, Tarrytown, NY.

Andrew Yaworsky (A)

Adelphi Values, Patient-centered Outcomes, Boston, Mass. Electronic address: andrew.yaworsky@adelphivalues.com.

Isabelle Guillemin (I)

IQVIA, Patient Centered Solutions, Lyon, France.

Meaghan Krohe (M)

Adelphi Values, Patient-centered Outcomes, Boston, Mass.

Leighann Litcher-Kelly (L)

Adelphi Values, Patient-centered Outcomes, Boston, Mass.

Megan McLafferty (M)

Adelphi Values, Patient-centered Outcomes, Boston, Mass.

Roger E Lamoureux (RE)

Adelphi Values, Patient-centered Outcomes, Boston, Mass.

Caitlyn Lowe (C)

Adelphi Values, Patient-centered Outcomes, Boston, Mass.

Mirna Chehade (M)

Mount Sinai Center for Eosinophilic Disorders, Departments of Pediatrics and Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.

Jonathan M Spergel (JM)

Division of Allergy-Immunology, Department of Pediatrics, The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa.

Kevin Weinfurt (K)

Department of Population Health Sciences, Duke University School of Medicine, Durham, NC.

Diane M Turner-Bowker (DM)

Adelphi Values, Patient-centered Outcomes, Boston, Mass.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH